EADV 2025｜Tralokinumab 可使中重度特应性皮炎患者获得稳定的长期应答

我是 Andrew Blauvelt 博士。我是一名来自美国马里兰州安那波利斯市的皮肤科医生。我在学术界工作了 19 年，随后从事临床试验 13 年，现在我担任多家制药公司的顾问。我在最新突破会议口头报告中介绍了一项关于药物 Tralokinumab 的研究。该药是一种针对中重度特应性皮炎的 IL-13 抑制剂，已经研究多年了。我们有五到六年的 Tralokinumab 治疗特应性皮炎患者的数据。在这项新研究中，我们基于长期收集的数据，回顾了患者在第 16 周的应答以及患者在第 16 周（即研究的前四个月）进行的活动。我们分析了 EASI75 应答者、EASI90 应答者，以及第 16 周 DLQI 评分为 0 或 1 的应答者。我们关注了那些初始表现良好的患者，并随访了五到六年，观察这些患者后来的情况。结果发现，第 16 周的反应高度预测了患者持续缓解症状的能力。这些达到 EASI 90 的患者，也就是我们在第 16 周时所称的超级应答者，五年内表现非常好。总结来说，研究结果是，如果你在最初四个月内应答良好，那么五年内保持良好状态的可能性很大。 

My name is Dr. Andrew Blauvelt. I'm a dermatologist from Annapolis, Maryland. I've spent 19 years in academics and then 13 years doing clinical trials, and I serve as a consultant now for a number of pharmaceutical companies. I'm going to be talking about in an oral presentation in the late-breaker session is a study with the drug Tralokinumab, which is an IL-13 blocker for moderate to severe atopic dermatitis. And so that drug has been studied for many years now. We have five-year, six-year data with Tralokinumab in patients with atopic dermatitis. So what we did in this new study with data that we've been collecting over time is look back at the patient's week 16 response and what the patients were doing at week 16, so the first four months of the study. And what we did is we looked at EASI75 responders, EASI90 responders, and then also responders that had a DLQI of 0/1 at week 16. So we looked at those initial patients who were doing very well and then examined over time, over five, six years, what happened to those patients. And what we found is that the week 16 response predicted in a high manner the ability to stay clear over time. So those EASI 90, what we call super responders at week 16, did really great over a five-year period. So the findings, again, are that if you have great response in the first four months, you're highly likely to do well for five years.